NXTC vs. LEXX, UNCY, CARA, SNSE, NBRV, IMRX, XLO, EYEN, BOLT, and VYNE
Should you be buying NextCure stock or one of its competitors? The main competitors of NextCure include Lexaria Bioscience (LEXX), Unicycive Therapeutics (UNCY), Cara Therapeutics (CARA), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), Immuneering (IMRX), Xilio Therapeutics (XLO), Eyenovia (EYEN), Bolt Biotherapeutics (BOLT), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical preparations" industry.
NextCure (NASDAQ:NXTC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking and institutional ownership.
In the previous week, Lexaria Bioscience had 4 more articles in the media than NextCure. MarketBeat recorded 7 mentions for Lexaria Bioscience and 3 mentions for NextCure. NextCure's average media sentiment score of 0.80 beat Lexaria Bioscience's score of 0.29 indicating that NextCure is being referred to more favorably in the media.
NextCure has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
42.7% of NextCure shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 11.9% of NextCure shares are held by company insiders. Comparatively, 7.6% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
NextCure currently has a consensus target price of $6.00, indicating a potential upside of 263.64%. Lexaria Bioscience has a consensus target price of $12.00, indicating a potential upside of 238.03%. Given NextCure's higher probable upside, research analysts clearly believe NextCure is more favorable than Lexaria Bioscience.
Lexaria Bioscience has higher revenue and earnings than NextCure. Lexaria Bioscience is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
NextCure's return on equity of -53.29% beat Lexaria Bioscience's return on equity.
NextCure received 75 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 63.64% of users gave NextCure an outperform vote.
Summary
NextCure beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.
Get NextCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NXTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NextCure Competitors List
Related Companies and Tools
